World

Russia registers new locally developed smallpox drug Neokh-14

Sep 06, 2026

Moscow [Russia], September 6: Anna Popova, head of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), announced that Russia has officially registered a new locally developed drug against smallpox, named Neokh-14.
Popova stated that the drug has proven effective and is used to treat infections caused by the smallpox virus, as well as monkeypox and cowpox.
She added that Neokh-14 was developed at the State Research Centre of Virology and Biotechnology 'Vector', which operates under the Russian Federal Service for Surveillance on Consumer Rights Protection.
Smallpox is a contagious viral disease that the World Health Organisation declared eradicated in 1980. However, concerns about its spread have resurfaced in recent years following monkeypox outbreaks in several countries.
In response, Russia has intensified efforts to develop new drugs and vaccines to counter any potential spread of the virus.
Source: Emirates News Agency

More news

Infosys: Differentiated AI strategy and a sharp focus on value unlock propels 29% sequential growth in AI revenues

Bengaluru (Karnataka) [India], October 23: Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in AI-first business consulting and technology services, delivered $5,145 million in Q2 revenues, year on year growth of 1.5% and sequential growth of 1.2% in constant currency. Operating margin was stable at 21.0%. EPS growth was 8.7% year on year in rupee terms. TCV of large deal wins was $5.2 billion, with 62% net new. Robust Q2 large deal TCV at $5.2 billion with 62% net new; lays solid foundation for future growth. FY 27 revenue guidance revised to 1%-2% and margin guidance retained at 20%-22%.

Oct 23, 2026